Effect of tapering methotrexate in rheumatoid arthritis patients after add-on iguratimod therapy.

Effect of tapering methotrexate in rheumatoid arthritis patients after add-on iguratimod therapy. - Effect of tapering MTX in RA patinents after add-on IGU theraoy.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027719

Enrollment

100

Registered

2017-06-12

Start date

2017-06-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis/remission

Interventions

add-on iguratimod tapering MTX continuing the treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: sustaining DAS28ESR remission more than 6 months

Exclusion criteria

Exclusion criteria: add-on another csDMARDs or bDMARDs within 8 weeks.

Design outcomes

Primary

Measure	Time frame
rate of sustaining remission after 36 weeks	—

Secondary

Measure	Time frame
ultrasound findings (power Doppler score, Grey scale score) SF-36, HAQ, dose of MTX	—

Countries

Japan

Contacts

Public ContactShuzo Yoshida

Osaka Medical College Department of Internal Medicine (4)

in1307@osaka-med.ac.jp+81-72-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026